Human Myeloperoxidase/MPO Antibody Summary
Accession # P05164
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of Human Myeloperoxidase/MPO by Western Blot.
Detection of Human Myeloperoxidase/MPO by Western Blot.Western blot shows lysates of HL‑60 human acute promyelocytic leukemia cell line and human neutrophil. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human Myeloperoxidase/MPO Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3174) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for Myeloperoxidase/MPO at approximately 60-65 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 2.
Detection of Human Myeloperoxidase/MPO by Simple WesternTM.
12-230 kDa separation system.
Detection of Human Myeloperoxidase/MPO by Simple WesternTM.Simple Western lane view shows lysates of human neutrophils, loaded at 0.2 mg/mL. A specific band was detected for Myeloperoxidase/MPO at approximately 65 kDa (as indicated) using 5 µg/mL of Goat Anti-Human Myeloperoxidase/MPO Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3174) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Myeloperoxidase (MPO) is a heme-containing enzyme belonging to the XPO subfamily of peroxidases. It is an abundant neutrophil and monocyte glycoprotein that catalyzes the hydrogen peroxide-dependent conversion of chloride, bromide, and iodide to multiple reactive species (1). Post-translational processing of MPO involves the insertion of a heme moiety and the proteolytic removal of both a propeptide and a 6 aa internal peptide (2). This results in a disulfide-linked dimer composed of a 60 kDa heavy and 12 kDa light chain that associate into a 150 kDa enzymatically active tetramer. The tetramer contains two heme groups and one disulfide bond between the heavy chains (2). Alternate splicing generates two additional isoforms of MPO, one with a 32 aa insertion in the light chain, and another with a deletion of the signal sequence and part of the propeptide (3). Human and mouse MPO share 87% aa sequence identity. MPO activity results in protein nitrosylation and the formation of 3-chlorotyrosine and dityrosine crosslinks (4‑6). Modification of ApoB100, as well as the lipid and cholesterol components of LDL and HDL, promotes the development of atherosclerosis (5, 7‑9). MPO is also associated with a variety of other diseases (1), and inhibits vasodilation in inflammation by depleting the levels of NO (10). Serum albumin functions as a carrier protein during MPO movement to the basolateral side of epithelial cells (11). MPO is stored in neutrophil azurophilic granules. Upon cellular activation, it is deposited into pathogen-containing phagosomes (2). While mice lacking MPO are impaired in clearing select microbial infections, MPO deficiency in humans does not necessarily result in heightened susceptibility to infections (12, 13).
- Klebanoff, S.J. (2005) J. Leukoc. Biol. 77:598.
- Hansson, M. et al. (2006) Arch. Biochem. Biophys. 445:214.
- Hashinaka, K. et al. (1988) Biochemistry 27:5906.
- van Dalen, C.J. et al. (2000) J. Biol. Chem. 275:11638.
- Hazen, S.L. and J.W. Heinecke (1997) J. Clin. Invest. 99:2075.
- Heinecke, J.W. et al. (1993) J. Clin. Invest. 91:2866.
- Podrez, E.A. et al. (1999) J. Clin. Invest. 103:1547.
- Bergt, C. et al. (2004) Proc. Natl. Acad. Sci. 101:13032.
- Hazen, S.L. et al. (1996) J. Biol. Chem. 271:23080.
- Eiserich, J.P. et al. (2002) Science 296:2391.
- Tiruppathi, C. et al. (2004) Proc. Natl. Acad. Sci. 101:7699.
- Aratani Y. et al. (2000) J. Infect. Dis. 182:1276.
- Kutter, D. (1998) J. Mol. Med. 76:669.
Citation for Human Myeloperoxidase/MPO Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
1 Citation: Showing 1 - 1
TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus
Authors: L Bossaller, A Christ, K Pelka, K Nündel, PI Chiang, C Pang, N Mishra, P Busto, RG Bonegio, RE Schmidt, E Latz, A Marshak-Ro
J. Immunol., 2016;197(4):1044-53.
Sample Types: Serum
Applications: ELISA Development
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Cell and Tissue Staining Kits
Reviews for Human Myeloperoxidase/MPO Antibody
Average Rating: 3 (Based on 1 Review)
Have you used Human Myeloperoxidase/MPO Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image